Experimental Drug Shrinks Mouse Tumors

A Cancer Cell study reports an experimental TGF-beta blocker eliminated tumors in many treated mice, with human trials planned for 2027.

Updated on Nov. 10, 2026 in Cancer

Bold flat-color editorial illustration of rounded tumor masses with a fibrous lattice wall peeling open to release small red cells, evoking immune access to cancer.
Researchers at MedPacto Inc. in Seoul reported that an experimental TGF-beta blocker eliminated many tumors in treated mice, with human trials planned for 2027. AI Illustration. Upload story photo >

Researchers led by Dr. Seong-Jin Kim of MedPacto Inc. in Seoul, South Korea, published findings Monday in the journal Cancer Cell describing an experimental TGF-beta blocker effective against pancreatic and breast cancer in mice. The drug targets a protein abundant in tumors but rare in healthy adult tissue.

Why it matters

Solid tumors shield themselves with a dense scar-like tissue, fueled by the signaling molecule TGF-beta, that keeps immune T cells out. The study suggests blocking TGF-beta locally may let killer T cells reach tumors, a strategy that could inform future cancer treatments if it translates to humans.

The study is a preclinical mouse investigation, with tumors disappearing in 75% of treated mice in one aggressive pancreatic cancer model. Human clinical trials are not expected to begin until 2027, so efficacy and safety in people remain unestablished.

The players

Cancer Cell

A peer-reviewed journal published by Cell Press that focuses on cancer biology and translational cancer research.

MedPacto Inc.

A Seoul, South Korea-based company developing the experimental TGF-beta blocker, which holds pending patents on the compound.

Dr. John J. Letterio

Director of the Angie Fowler Adolescent and Young Adult Cancer Institute at UH Rainbow in Cleveland, Ohio, and co-author of the study.

The details

Scientists engineered a TGF-beta blocker tagged to stick to a tumor-associated protein, which loosened the tumor's fibrous tissue and allowed killer T cells to move in. Cured mice later rejected the same cancer when it was reintroduced months afterward, and MedPacto holds pending patents on the compound.

Timeline

  1. Study published Monday, November 9, 2026, in Cancer Cell.

  2. Human clinical trials of the drug are planned to begin in 2027.

Health Landscape

TGF-beta blockade has been studied for years as a way to overcome the immune-excluding scar tissue of solid tumors. This tumor-targeted approach aims to reduce the broad systemic effects that have limited earlier versions of the strategy.

This is an early preclinical result, so no treatment is available to patients yet. Any future therapy would need to pass human safety and efficacy trials before it could reach clinics.

The takeaway

Animal results are an important first step, but they do not guarantee human benefit. Readers should watch for the 2027 trial outcomes before drawing conclusions about the therapy.

What happens next

Human clinical trials of the TGF-beta blocker are planned to begin in 2027.

Further reading

Explore more in our Cancer coverage for context on how researchers are approaching tumor immunity.